Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Curacle","sponsor":"Th\u00e9a Open Innovation","pharmaFlowCategory":"D","amount":"$2,163.5 million","upfrontCash":"$6.0 million","newsHeadline":"CURACLE and Th\u00e9a Announce Licensing and Collaboration Agreement for the Development and Commercialization of Orally Administered Treatment for Diabetic Macular Edema and Wet-AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Curacle"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Doses First Patient in Clinical Trial for RNAi Therapeutic OLX10212 for Dry and Wet Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"OliX Pharmaceutical"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration Following Dose Level 1 Safety Data","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"PharmAbcine"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"OliX Pharmaceutical"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              OliX Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration

              Details:

              OLX10212 is a VEGF Modulator oligonucleotide drug administered via intravitreal injection, currently being investigated for the treatment of Age-Related Macular Degeneration.

              Lead Product(s): OLX10212

              Therapeutic Area: Ophthalmology Product Name: OLX10212

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmAbcine

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration Following Do...

              Details:

              PMC-403 is an antibody therapeutic candidate with a novel mechanism of action in which it activates the TIE2 receptor and normalizes the leaky pathological blood vessels, which is investigated for the treatment of Neovascular Age-related Macular Degeneration.

              Lead Product(s): PMC-403

              Therapeutic Area: Ophthalmology Product Name: PMC-403

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OliX Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OliX Pharmaceuticals Doses First Patient in Clinical Trial for RNAi Therapeutic OLX10212 for Dry and Wet Age-related Macular Degeneration

              Details:

              OLX10212, an investigational RNAi therapeutic intended for the treatment of AMD. It targets inflammation pathways (blockade of VEGF) and offers increased specificity over conventional siRNA having the additional benefit of impermanence over gene therapy.

              Lead Product(s): OLX10212

              Therapeutic Area: Ophthalmology Product Name: OLX10212

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Curacle

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CURACLE and Théa Announce Licensing and Collaboration Agreement for the Development and Commercialization of Orally Administered Treatment for Diabetic Macular Edema and W...

              Details:

              Under the agreement, CURACLE will retain the marketing rights of CU06-RE, the first orally administered treatment for diabetic macular edema and wet-AMD in all Asia countries while Théa will have the marketing rights in all other countries around the world.

              Lead Product(s): CU06

              Therapeutic Area: Ophthalmology Product Name: CU06-RE

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Théa Open Innovation

              Deal Size: $2,163.5 million Upfront Cash: $6.0 million

              Deal Type: Collaboration October 27, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY